Alto Neuroscience (ANRO) Accumulated Expenses (2023 - 2026)

Alto Neuroscience has disclosed Accumulated Expenses across 4 years of filings, most recently posting $7.6 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $7.6 million, up 29.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.6 million (up 29.58% YoY), and the FY2025 annual result was $8.9 million, up 5.14% from the prior year.
• Accumulated Expenses came in at $7.6 million for Q1 2026 at Alto Neuroscience, down from $8.9 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $8.9 million in Q4 2025 to a low of $4.4 million in Q1 2024.
• The 4-year median for Accumulated Expenses is $6.7 million (2025), against an average of $6.7 million.
• Across the five-year window, Accumulated Expenses surged 85.82% in 2024 and dropped 15.16% in 2025, its largest moves.
• Alto Neuroscience's Accumulated Expenses stood at $4.5 million in 2023, then jumped by 85.82% to $8.4 million in 2024, then gained by 5.14% to $8.9 million in 2025, then decreased by 14.13% to $7.6 million in 2026.
• The last three Accumulated Expenses figures came in at $7.6 million (Q1 2026), $8.9 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.